Home » Stocks » ATXI

Avenue Therapeutics, Inc. (ATXI)

Stock Price: $4.52 USD 0.29 (6.86%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $4.50 -0.02 (-0.44%) May 7, 7:39 PM
Market Cap 73.02M
Revenue (ttm) n/a
Net Income (ttm) -5.15M
Shares Out 16.51M
EPS (ttm) -0.31
PE Ratio n/a
Forward PE 17.99
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $4.52
Previous Close $4.23
Change ($) 0.29
Change (%) 6.86%
Day's Open 4.29
Day's Range 4.28 - 4.69
Day's Volume 195,763
52-Week Range 2.85 - 12.34

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK, April 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Avenue Therapeutics Inc. ("Avenue" or the "Company") (NASDAQ: ATXI).  Such investors are advised...

2 weeks ago - PRNewsWire

Avenue Therapeutics (ATXI) has been struggling lately, but the selling pressure may be coming to an end soon

2 weeks ago - Zacks Investment Research

NEW YORK, April 13, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Avenue Therapeutics Inc. ("Avenue" or the "Company") (NASDAQ: ATXI).  Such investors are advised...

3 weeks ago - PRNewsWire

The FDA Has Not Provided a Decision Regarding the NDA The FDA Has Not Provided a Decision Regarding the NDA

3 weeks ago - GlobeNewsWire

NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced that...

4 months ago - GlobeNewsWire

NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced that...

4 months ago - GlobeNewsWire

NEW YORK, Oct. 14, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Avenue Therapeutics, Inc. ("Avenue Therapeutics" or the "Company") (NASDAQ: ATXI). Such investors ...

6 months ago - PRNewsWire

Avenue Therapeutics' (ATXI) NDA seeking an approval for its pipeline candidate tramadol to treat postoperative pain gets a CRL from the FDA, based on potential safety concerns. Shares down.

6 months ago - Zacks Investment Research

Shares of micro-cap biopharma Avenue Therapeutics Inc (NASDAQ: ATXI) are plummeting on above-average volume after a binary event panned out against the company. What Happened: New York-based Avenue said...

6 months ago - Benzinga

Management to Host Conference Call at 8:30 a.m. ET Management to Host Conference Call at 8:30 a.m. ET

6 months ago - GlobeNewsWire

NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announc...

7 months ago - GlobeNewsWire

Avenue Therapeutics (ATXI) reports a wider-than-expected loss in the second quarter of 2021.

8 months ago - Zacks Investment Research

NEW YORK, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today reported...

8 months ago - GlobeNewsWire

Avenue Therapeutics' (ATXI) sole pipeline candidate, tramadol, is under review. With lower clinical activities, operating expenses are likely to have declined during the second quarter.

9 months ago - Zacks Investment Research

Avenue Therapeutics, Inc. (ATXI) closed the most recent trading day at $10.30, moving -1.9% from the previous trading session.

9 months ago - Zacks Investment Research

Avenue Therapeutics, Inc. (ATXI) closed the most recent trading day at $10.40, moving -1.61% from the previous trading session.

9 months ago - Zacks Investment Research

Publication highlights IV tramadol 50 mg demonstrated a statistically significant benefit (p-value < 0.05) over placebo for primary and all key secondary efficacy endpoints Publication highlights IV tra...

9 months ago - GlobeNewsWire

Is (ATXI) Outperforming Other Medical Stocks This Year?

9 months ago - Zacks Investment Research

Avenue Therapeutics, Inc. (ATXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

10 months ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Avenue Therapeutics

10 months ago - Zacks Investment Research

Is (ATXI) Outperforming Other Medical Stocks This Year?

10 months ago - Zacks Investment Research

To combat market volatility, it is of utmost importance to create a portfolio of low-beta stocks.

Other stocks mentioned: BJ, FRO, ICLK, PRQR
10 months ago - Zacks Investment Research

Selecting breakout stocks continue to be one of the most popular methods utilized by active investors.

Other stocks mentioned: CALX, ECOM, MGIC
10 months ago - Zacks Investment Research

NEW YORK, June 05, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announce...

11 months ago - GlobeNewsWire

Small Drug Industry Prospects Bright Amid Coronavirus Gloom

Other stocks mentioned: CNCE, MEIP, NERV, OCUL
11 months ago - Zacks Investment Research

Avenue (ATXI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

11 months ago - Zacks Investment Research

Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.

Other stocks mentioned: AAWW, BJ, HEAR, VERI
11 months ago - Zacks Investment Research

NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today reported ...

11 months ago - GlobeNewsWire

Tech rally is here to stay on solid fundamentals. Bet on stocks that are yet to reclaim their 52-week high levels despite the recent uptrend.

Other stocks mentioned: BL, INSG, MTSI, WK, XLK
1 year ago - Zacks Investment Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 27th

Other stocks mentioned: CANF, GFI, MN
1 year ago - Zacks Investment Research

Avenue Therapeutics (ATXI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 year ago - Zacks Investment Research

A handful of small-cap stocks have skyrocketed defying the coronavirus-induced market mayhem and extreme volatility.

Other stocks mentioned: CUE, GAIA, PJT, SPTN
1 year ago - Zacks Investment Research

Avenue Therapeutics, Inc. (ATXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

1 year ago - Zacks Investment Research

Avenue Therapeutics Update: Shares A Steal Ahead Of Known PDUFA Action Date

1 year ago - Seeking Alpha

NEW YORK, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announce...

1 year ago - GlobeNewsWire

Avenue Therapeutics Submits Its NDA; Shares Still Cheap

1 year ago - Seeking Alpha

NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announce...

1 year ago - GlobeNewsWire

NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, announced toda...

1 year ago - GlobeNewsWire

NEW YORK, Oct. 18, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announce...

1 year ago - GlobeNewsWire

Shares of Avenue Therapeutics have done virtually nothing over the last four months.

1 year ago - Seeking Alpha

Avenue Therapeutics, Inc. (ATXI) CEO Dr.

1 year ago - Seeking Alpha

Avenue Therapeutics (NASDAQ: ATXI)'s second Phase 3 trial of IV tramadol for the treatment of postoperative pain following abdominoplasty is a success.

1 year ago - Benzinga

About ATXI

Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was incorporated in 2015 and is based in New York, New York.

Industry
Biotechnology
IPO Date
Jun 27, 2017
Stock Exchange
NASDAQ
Ticker Symbol
ATXI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for ATXI stock is "Buy." The 12-month stock price forecast is 9.00, which is an increase of 99.12% from the latest price.

Price Target
$9.00
(99.12% upside)
Analyst Consensus: Buy